Sign Up
Stories
HelixBind's RaPID/BSI Assay in Sepsis Detection
Share
Infection Control Market Challenges
Rising Superbugs and Infection Control
FDA Fast Track for AdrenoMed's Enibarcim...
T2 Biosystems Wins Lyme Diagnostics Priz...
Overview
API
HelixBind, Inc. showcases the effectiveness of RaPID/BSI assay in detecting bloodstream infections in patients with sepsis, outperforming follow-up cultures. The study was conducted at Tufts Medical Center, highlighting the potential for personalized antimicrobial therapy and stewardship.
Ask a question
How could the effectiveness of HelixBind's RaPID/BSI assay influence the development of similar diagnostic tools in the future?
How might the use of HelixBind's RaPID/BSI assay impact the diagnosis and treatment of sepsis?
What are the potential implications of personalized antimicrobial therapy and stewardship in sepsis management?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage